Home » Stocks » MRUS

Merus N.V. (MRUS)

Stock Price: $27.22 USD 2.19 (8.75%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $27.50 +0.28 (1.03%) Jan 21, 4:42 PM
Market Cap 848.13M
Revenue (ttm) 28.52M
Net Income (ttm) -83.53M
Shares Out 29.06M
EPS (ttm) -2.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $27.22
Previous Close $25.03
Change ($) 2.19
Change (%) 8.75%
Day's Open 26.24
Day's Range 24.90 - 27.50
Day's Volume 1,303,692
52-Week Range 10.50 - 27.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 9 hours ago

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, ...

GlobeNewsWire - 2 days ago

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, f...

Benzinga - 2 days ago

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...

Other stocks mentioned: ACRS, CYAD, GRTS, NERV, TENX
PRNewsWire - 2 days ago

INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: ...

Other stocks mentioned: LLY
GlobeNewsWire - 1 week ago

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific ...

GlobeNewsWire - 1 week ago

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developin...

Zacks Investment Research - 1 week ago

The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.

GlobeNewsWire - 2 weeks ago

NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer NRG1 fusions are rare mutations in many types of solid tumors, includi...

GlobeNewsWire - 1 month ago

UTRECHT, The Netherlands and STAMFORD, Conn., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multi-specific a...

GlobeNewsWire - 2 months ago

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific a...

GlobeNewsWire - 2 months ago

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developin...

GlobeNewsWire - 2 months ago

–Clinical data and program update planned for lead program Zenocutuzumab (“Zeno”) in 2Q 2021–– MCLA-129 expected to enter clinic in 2021 –

GlobeNewsWire - 3 months ago

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology comp...

Zacks Investment Research - 4 months ago

Merus (MRUS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecif...

GlobeNewsWire - 5 months ago

– Lead program Zenocutuzumab remains on track –– Dr. Andrew Joe appointed Chief Medical Officer –– Merus extends cash runway into 2H 2022 –

GlobeNewsWire - 5 months ago

Dr. Joe brings seasoned research and development leadership and deep expertise in the clinical development of immuno-oncology, antibody, and targeted therapies for cancer Dr. Joe brings season...

GlobeNewsWire - 5 months ago

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecif...

GlobeNewsWire - 6 months ago

Caris to provide DNA and RNA molecular testing to support  patient identification and enrollment for Merus’ Zenocutuzumab Phase 1/2 eNRGy trial

GlobeNewsWire - 8 months ago

– MCLA-128, zenocutuzumab, independent epidemiology analysis reaffirms significant clinical and commercial potential in NRG1 fusion cancers –– MCLA-117 demonstrates limited clinical activity i...

Zacks Investment Research - 8 months ago

Merus NV (MRUS) delivered earnings and revenue surprises of -25.93% and -21.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Merus: Catalyst Filled 2020 For Biclonics Platform, Concerns Remain

GlobeNewsWire - 1 year ago

— Bill Lundberg, M.D., nominated for appointment as Chief Executive Officer —— Ton Logtenberg, Ph.D., to step down after 16 years of leadership —— Transition to occur December 31, 2019 —

Zacks Investment Research - 1 year ago

Merus N.V. (MRUS) delivered earnings and revenue surprises of 14.89% and 15.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announc...

GlobeNewsWire - 1 year ago

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage bispecific antibody company developing Biclonics®, today announce...

GlobeNewsWire - 1 year ago

Tumor shrinkage observed in three patients harboring NRG1 fusions (two pancreatic, one non-small cell lung cancer) presented by investigators at AACR-NCI-EORTC International Conference on Mole...

The Motley Fool - 1 year ago

With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.

Other stocks mentioned: MGNX, SGEN, ZYME
GlobeNewsWire - 1 year ago

Company to host investor call on Monday, October 28th at 8:00AM ET Company to host investor call on Monday, October 28th at 8:00AM ET

Zacks Investment Research - 1 year ago

Merus N.V. (MRUS) delivered earnings and revenue surprises of -5.56% and -27.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

UTRECHT, The Netherlands, Aug. 19, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,...

Zacks Investment Research - 1 year ago

Merus is looking like an interesting pick from a technical perspective.

Zacks Investment Research - 1 year ago

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Merus N.V. (MRUS).

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Merus.

Seeking Alpha - 1 year ago

Merus is demonstrating strong trading analytics amid the recent market hiccup relating to Dr. Gottlieb's sudden departure.

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors. In addition, its res... [Read more...]

Industry
Biotechnology
IPO Date
May 19, 2016
CEO
Sven Lundberg
Employees
87
Stock Exchange
NASDAQ
Ticker Symbol
MRUS
Full Company Profile

Financial Performance

In 2019, Merus N.V.'s revenue was $31.13 million, a decrease of -18.88% compared to the previous year's $38.38 million. Losses were -$55.15 million, 94.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Merus N.V. stock is "Buy." The 12-month stock price forecast is 22.57, which is a decrease of -17.08% from the latest price.

Price Target
$22.57
(-17.08% downside)
Analyst Consensus: Buy